KLRB1 and Miyoshi myopathy: Blockade of CD161 restores tissue residency and cytotoxicity of CD8+ T cells and enhances chimeric antigen receptor T‐cell (CAR‐T) activity, providing a potential immunotherapeutic target in MM.